| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/28/2011 | US20110184031 G-Protein-Conjugated Receptor Agonist |
| 07/28/2011 | US20110184023 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide |
| 07/28/2011 | US20110184015 Novel derivatives of pyrroloindole which are inhibitors of hsp90, compositions containing same, and use thereof |
| 07/28/2011 | US20110184013 Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors |
| 07/28/2011 | US20110184009 Camptothecin derivatives as chemoradiosensitizing agents |
| 07/28/2011 | US20110184004 Predictive marker for egfr inhibitor treatment |
| 07/28/2011 | US20110184001 Inhibitors of bruton's tyrosine kinase |
| 07/28/2011 | US20110183997 Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors |
| 07/28/2011 | US20110183989 Saturated bicyclic heterocyclic derivatives as smo antagonists |
| 07/28/2011 | US20110183988 Compounds and methods for kinase modulation, and indications therefor |
| 07/28/2011 | US20110183987 Stereoselective Synthesis of Bicyclic Heterocycles |
| 07/28/2011 | US20110183986 Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors |
| 07/28/2011 | US20110183985 Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
| 07/28/2011 | US20110183984 Small molecule inhibitors of lck sh2 domain binding |
| 07/28/2011 | US20110183983 Heterocyclic compound as protein kinase inhibitor |
| 07/28/2011 | US20110183981 Heterocyclic inhibitors of mek and methods of use thereof |
| 07/28/2011 | US20110183979 Nitrogen-containing heteroaryl derivatives |
| 07/28/2011 | US20110183977 Benzene, pyridine, and pyridazine derivatives |
| 07/28/2011 | US20110183975 Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| 07/28/2011 | US20110183974 1,2,4-oxadiazole substituted piperidine and piperazine derivatives as smo antagonists |
| 07/28/2011 | US20110183973 Novel Compounds |
| 07/28/2011 | US20110183972 Aromatic ring fused triazine derivatives and uses thereof |
| 07/28/2011 | US20110183971 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 07/28/2011 | US20110183965 6-aminoisoquinoline compounds |
| 07/28/2011 | US20110183964 Hydroxamate-based inhibitors of deacetylases b |
| 07/28/2011 | US20110183962 Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| 07/28/2011 | US20110183961 Azetidine polysubstituted compounds, preparation thereof, and therapeutic application thereof |
| 07/28/2011 | US20110183955 2-Aminocarbonyl Substituted Piperazine or Diaza-Cyclic Compounds as Apoptosis Protein Inhibitors (Iap) Modulators |
| 07/28/2011 | US20110183954 Tricyclic 2,4-diamino-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders |
| 07/28/2011 | US20110183952 New chemical compounds |
| 07/28/2011 | US20110183949 Use of Fulvestrant in the Treatment of Resistant Breast Cancer |
| 07/28/2011 | US20110183948 Treatment of fibrotic conditions using hedgehog inhibitors |
| 07/28/2011 | US20110183947 Alpha-keto heterocycles as faah inhibitors |
| 07/28/2011 | US20110183945 Long acting curcumin derivative, preparation method and pharmaceutical use thereof |
| 07/28/2011 | US20110183944 SUSTAINED-RELEASE NSAID/HMG CoA REDUCTASE INHIBITOR COMPOSITIONS |
| 07/28/2011 | US20110183938 1,7-diazacarbazoles and methods of use |
| 07/28/2011 | US20110183933 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 07/28/2011 | US20110183931 Potent lna oligonucleotides for the inhibition of hif-1a expression |
| 07/28/2011 | US20110183930 Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives |
| 07/28/2011 | US20110183926 Treatment using continuous low dose application of sugar analogs |
| 07/28/2011 | US20110183924 Methods and systems for annotating biomolecular sequences |
| 07/28/2011 | US20110183923 Peptide antagonists of zonulin and methods for use of the same |
| 07/28/2011 | US20110183918 Method of Treating Leukemia Using Rcie Prolamin |
| 07/28/2011 | US20110183917 P53 Activator Peptides |
| 07/28/2011 | US20110183916 Apo-2 Ligand |
| 07/28/2011 | US20110183915 Small Molecule Cancer Treatments that cause Necrosis in Cancer Cells but do not Affect Normal Cells |
| 07/28/2011 | US20110183897 Variant activin receptor polypeptides |
| 07/28/2011 | US20110183895 Polyheterocyclic compounds highly potent as hcv inhibitors |
| 07/28/2011 | US20110183893 Non-natural mic proteins |
| 07/28/2011 | US20110183890 Methods for modulating angiogenesis via dystrophin dp71 |
| 07/28/2011 | US20110183888 Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
| 07/28/2011 | US20110183884 Pan-antiviral peptides for protein kinase inhibition |
| 07/28/2011 | US20110183416 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 07/28/2011 | US20110183015 Medical composition for inhibiting the growth of cancer stem cell |
| 07/28/2011 | US20110183014 Product containing extract from zanthoxylum avicennae (lam.) dc., and preparation process and use thereof |
| 07/28/2011 | US20110182998 Microspheres useful for therapeutic vascular embolization |
| 07/28/2011 | US20110182989 Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites |
| 07/28/2011 | US20110182985 Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| 07/28/2011 | US20110182983 Human immortalised neural precursor cell line |
| 07/28/2011 | US20110182980 Composition for suppressing expression of target gene |
| 07/28/2011 | US20110182978 Activated nitric oxide donors and methods of making and using thereof |
| 07/28/2011 | US20110182973 Polymerase inhibitors and the use thereof for the treatment of tumors |
| 07/28/2011 | US20110182945 Semi-allogenic anti-tumour vaccine with hla haplo-identical antigen-presenting cells |
| 07/28/2011 | US20110182944 Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein |
| 07/28/2011 | US20110182943 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
| 07/28/2011 | US20110182939 Vaccine Adjuvants |
| 07/28/2011 | US20110182933 Modified vaccinia ankara virus variant |
| 07/28/2011 | US20110182926 Minigene |
| 07/28/2011 | US20110182920 Identification of a novel cysteine-rich cell penetrating peptide |
| 07/28/2011 | US20110182914 Methods and compositions |
| 07/28/2011 | US20110182907 Anti-alpha-Enolase I Antibodies for Diagnosis and Treatment of alpha-Enolase I-Associated Diseases |
| 07/28/2011 | US20110182905 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same |
| 07/28/2011 | US20110182904 Antibodies to bone morphogenic proteins and receptors therefor and methods for their use |
| 07/28/2011 | US20110182901 Full length large t tumor antigen of merkel cell polyomavirus as a therapeutic target in merkel cell carcinoma |
| 07/28/2011 | US20110182895 Antibody variants |
| 07/28/2011 | US20110182893 Prevention and treatment of amyloidogenic diseases |
| 07/28/2011 | US20110182892 Methods to identify responsive patients |
| 07/28/2011 | US20110182891 Pharmaceutical dosage form comprising polymeric carrier composition |
| 07/28/2011 | US20110182890 Anti-pleiotrophin antibodies and methods of use thereof |
| 07/28/2011 | US20110182888 Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator |
| 07/28/2011 | US20110182887 Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| 07/28/2011 | US20110182886 Compositions and methods for inhibiting tumor progression |
| 07/28/2011 | US20110182884 P-cadherin antibodies |
| 07/28/2011 | US20110182882 Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof |
| 07/28/2011 | US20110182881 Signature and determinants associated with metastasis and methods of use thereof |
| 07/28/2011 | US20110182880 Combination Therapies Against Cancer |
| 07/28/2011 | US20110182872 Methods of analysis of polymorphisms and uses thereof |
| 07/28/2011 | US20110182870 Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| 07/28/2011 | US20110182819 Methods and Compounds for Promoting Vessel Regression |
| 07/28/2011 | US20110182815 Method for the detection of enzymatic activity with magnetically functionalized substrates |
| 07/28/2011 | US20110182814 Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma |
| 07/28/2011 | US20110182805 Nanoparticle fabrication methods, systems, and materials |
| 07/28/2011 | CA2787756A1 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| 07/28/2011 | CA2787722A1 A new series of artemisinin derivatives and process for preparation thereof |
| 07/28/2011 | CA2787714A1 Inhibitors of pi3 kinase |
| 07/28/2011 | CA2787369A1 Modified melk peptides and vaccines containing the same |
| 07/28/2011 | CA2787156A1 Synthetic nanostructures including nucleic acids and/or other entities |
| 07/28/2011 | CA2786824A1 Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease |
| 07/28/2011 | CA2785907A1 Ron binding constructs and methods of use thereof |
| 07/28/2011 | CA2785661A1 Polypeptide heterodimers and uses thereof |